Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma, Large B-Cell, Diffuse × Decitabine × Clear all

Phase

Phase 2 4 Phase 1 3 Phase 3 2 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 24 Myelodysplastic Syndromes 11 Leukemia 7 Recurrence 5 Leukemia, Myelomonocytic, Chronic 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Myelodysplastic-Myeloproliferative Diseases 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Biphenotypic, Acute 2 Blast Crisis 2 Thrombocytopenia 1 Skin Neoplasms 1 Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden 1 Prostatic Neoplasms 1 Peripheral Blood Stem Cell Transplantation 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Myeloproliferative Disorders 1 Myeloid Malignancies 1 Mesothelioma, Malignant 1 Medulloblastoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphodepleting Chemotherapy 1

Interventions

Rituximab 42 Cyclophosphamide 36 Vincristine 21 Lenalidomide 20 Doxorubicin 20 Prednisone 18 Etoposide 14 Gemcitabine 11 Peripheral Blood Stem Cell Transplantation 9 fludarabine 8 Carboplatin 8 ibrutinib 7 fludarabine phosphate 7 Ifosfamide 7 Filgrastim 7 Bendamustine Hydrochloride 7 Oxaliplatin 6 Methotrexate 6 Vorinostat 5 R-CHOP protocol 5 Prednisolone 5 Bortezomib 5 venetoclax 4 tafasitamab 4 polatuzumab vedotin 4 pegfilgrastim 4 obinutuzumab 4 Mycophenolic Acid 4 Granulocyte Colony-Stimulating Factor 4 Dexamethasone 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02951728 2020-03-11

DR-CHOP

Ruijin Hospital

Phase 1/2 Unknown

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡